Investor Ideas ‘Potcast’; #Cannabis News
and Stocks on the Move; (TSX: $ACB.TO),
(CSE: $ATT.C), (TSXV: $ICC.V), (TSX: $TGOD.TO)
New Frontier
Data Adjusts CA Projections
Pt. Roberts, WA; Delta, BC – May 22, 2018
(Investorideas.com Newswire) www.Investorideas.com, a global news source
covering leading sectors including marijuana and hemp stocks and its “potcast’
site, www.potcasts.ca release today’s edition of
its new series, Investorideas.com potcasts - cannabis news and stocks to watch plus
insight from thought leaders and experts.
Listen to the podcast:
Read this in full at http://www.investorideas.com/news/2018/cannabis/05222Potcast-StocksToWatch.asp
Today’s podcast overview/transcript:
Good afternoon and welcome to
Investorideas.com potcasts-
following cannabis news, stocks to watch as well as insight from thought
leaders and experts . Today we are looking at announcements from Aurora Cannabis Inc. (TSX : ACB , OTCQB: ACBFF), Abattis Bioceuticals Corp. (CSE: ATT ,OTC: ATTBF), ICC Labs Inc. (TSX-V: ICC ) and The Green Organic Dutchman Holdings Ltd. (TSX: TGOD).
Before the other announcements however we look
at New Frontier Data, the authority in data, analytics and business
intelligence in the cannabis industry, has refined the state market projections
for California in light of the state’s recent lower than expected cannabis
excise-tax revenues for the first quarter of 2018. The state collected $33.6
million between January 1 and March 31, which put them significantly below the
original of $175 million within the first six months of 2018. New Frontier Data has reduced the latest
sales projections for 2018 from $3.8 billion to $1.9 billion. And by 2025, our
forecast for total California sales to be $4.72 billion instead our previously
projected $6.7 billion.
New Frontier Data looked at two key aspects of the California market;
their analysts redefined what a legal medical patient is and lowered the
conversation rate for illicit market consumers transitioning to legal adult-use
market consumers.
Next looking at Aurora Cannabis Inc. and CTT Pharmaceutical Holdings Inc.
who today announced that Aurora is acquiring an initial 9.14% ownership
interest in CTT via way of a non-brokered private placement in the form of a
US$1 million 5% convertible debenture. The agreement includes an issuance of
warrants enabling Aurora to increase ownership to 42.5%.
CTT will now provide Aurora with global exclusivity to develop,
manufacture and market CTT’s novel oral thin films wafers. The companies will
work jointly towards obtaining Health Canada approval for introduction of the
new products on the Canadian market, as well as obtaining commercial access to
other international jurisdictions in which Aurora is active.
A little about CTT; they’re an Ontario based global leader in the
development of dose specific fast dissolving oral thin film wafers that provide
a dose specific, smoke-free delivery of medical cannabis or other active
ingredients. CTT’s oral thin film wafer is made from FDA approved non-medical
ingredients used in several pharmaceutical formulations and provides the effective
oral delivery of a specific dose with rapid onset of action within 5-10 minutes
after dosing. Clinical research undertaken by CTT indicates the oral wafer
delivery of THC into the blood steam was approximately 40% quicker compared to
edible form factors, as well as resulted in approximately 28% more THC in the
blood stream at peak bioavailability levels.
Abattis Bioceuticals Corp. announced the
addition of three new vaporizers to its product line today. Since the Company’s
acquisition of Green Tree Therapeutics earlier this year, Abattis has been
working to expand its retail presence and product line and is now ready to
release its first three vaporizers, the VB-1, VB-2 and the KB-1.
”We believe that
the future of the cannabis vaporizer market is in branding, concentrates and
ancillary products,” stated Rob Abenante, President and CEO of Abattis. “Users
in the retail space are looking for functional, discreet and durable products
and we feel that our new titillating product line will meet all these demands.
In this, we are excited to take another step towards our goal of becoming a
complete one-stop provider of downstream cannabis solutions,” added Mr.
Abenante.
ICC Labs Inc. announced that it
has signed a letter of intent with CanPharma GmbH a licensed importer and
wholesaler of narcotics in the Federal Republic of Germany.
Through its relationship with CanPharma, ICC Labs intends to export to
Germany CBD isolate, oils and other derivatives, as well as various medicinal
THC cannabis products, including dried flowers and cannabis extracts from their
facilities in Uruguay and Colombia. The export arrangement for THC cannabis
products is subject to receipt of the requisite regulatory approvals and the
negotiation of definitive agreements by the end of second quarter this year.
Germany, with a population of 83 million people, €3.3 trillion in GDP
and €320 billion of healthcare expenditure, is home to Europe’s largest medical
cannabis market. Germany is already leading the way among European countries
with a market value of US$11.9 billion.(1)
Finally looking at The Green Organic Dutchman Holdings Ltd. who
announced that the Company has entered into an exclusive agreement with CBx
Enterprises LLC for the licensing of the Evolab and CBx Sciences brands and proprietary
technologies and formulations within Canada and other international
jurisdictions outside of the USA.
Based in Colorado, the CBx team brings decades of experience developing
and marketing a diverse array of unique, first-to-market medical and recreational
cannabis products. The licensing arrangement will immediately expand TGOD’s
product and technology portfolio, and position the Company for the successful
development of new products as Canadian and global product requirements and
standards rapidly evolve.
Evolab
is a top cannabinoid vaporization brand that has gained significant market
share through the creation of highly differentiated products in a very
competitive and saturated market. Evolab’s proprietary technologies and
industry-leading extraction efficiencies allow for the derivation of
pharmaceutical-grade cannabinoid oils and strain-specific terpenes without the
use of any harmful solvents or cutting-agents. These technologies and formulations
lead to the creation of much cleaner and safer full-plant oils for vaporization
without the introduction of chemicals commonly found in the e-vape industry.
Investor
ideas reminds all listeners to read our disclaimers and disclosures
on the Investorideas.com website and this podcast is not an endorsement to
buy products or services or securities. Investors are reminded all
investment involves risk and possible loss of investment
on the Investorideas.com website and this podcast is not an endorsement to
buy products or services or securities. Investors are reminded all
investment involves risk and possible loss of investment
Subscribe to the new cannabis podcast series:
Investorideas.com podcasts are also available on
iTunes, Google Play Music, Stitcher and Tunein.
About Investorideas.com - News that Inspires
Big Ideas
Investorideas.com is
a meeting place for global investors, featuring news, stock directories, video,
company profiles, interviews and more in leading sectors.
Investorideas.com
cannabis/marijuana and hemp content now includes http://cannabisstocknews.blogspot.com on Blogger.com: the Investorideas.com news and stock
directory pages, a cannabis investor group on Linkedin.com , the 420 Cannabis
Investor ideas www.420cannabisinvestorideas.com, and the new AI site Global Cannabis Investing at www.Globalcannabisinvesting.com
Disclaimer/Disclosure: Investorideas.com is
a digital publisher of third party sourced news, articles and equity research
as well as creates original content, including video, interviews and articles.
Original content created by investorideas is protected by copyright laws other
than syndication rights. Our site does not make recommendations for purchases
or sale of stocks, services or products. Nothing on our sites should be
construed as an offer or solicitation to buy or sell products or securities.
All investment involves risk and possible loss of investment. This site is
currently compensated for news publication and distribution, social media and
marketing, content creation and more. Contact each company directly regarding
content and press release questions. Disclosure is posted for each compensated
news release, content published /created if required but otherwise the news was
not compensated for and was published for the sole interest of our readers and
followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp.
Additional info
regarding BC Residents and global Investors: Effective September 15 2008 - all
BC investors should review all OTC and Pink sheet listed companies for
adherence in new disclosure filings and filing appropriate documents with
Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations
of each country.
To sponsor this podcast or be a guest
Contact Investorideas.com
800-665-0411
No comments:
Post a Comment